BE881680A - Composition pharmaceutique a base d'acylcarnitine pour le traitement d'un metabolisme cerebral altere et methode utilisee a cet effet - Google Patents

Composition pharmaceutique a base d'acylcarnitine pour le traitement d'un metabolisme cerebral altere et methode utilisee a cet effet

Info

Publication number
BE881680A
BE881680A BE0/199368A BE199368A BE881680A BE 881680 A BE881680 A BE 881680A BE 0/199368 A BE0/199368 A BE 0/199368A BE 199368 A BE199368 A BE 199368A BE 881680 A BE881680 A BE 881680A
Authority
BE
Belgium
Prior art keywords
acylcarnitine
treatment
pharmaceutical composition
method used
composition based
Prior art date
Application number
BE0/199368A
Other languages
English (en)
French (fr)
Original Assignee
Cavazza Claudio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT7947976A external-priority patent/IT1206954B/it
Priority claimed from IT50795/79A external-priority patent/IT1164062B/it
Application filed by Cavazza Claudio filed Critical Cavazza Claudio
Publication of BE881680A publication Critical patent/BE881680A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BE0/199368A 1979-02-12 1980-02-12 Composition pharmaceutique a base d'acylcarnitine pour le traitement d'un metabolisme cerebral altere et methode utilisee a cet effet BE881680A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT7947976A IT1206954B (it) 1979-02-12 1979-02-12 Agenti terapeutici a base di un acil derivato della carnitina per la cura di vasculopatie periferiche
IT50795/79A IT1164062B (it) 1979-11-09 1979-11-09 Composizione farmaceutica comprendente una acil-carnitina per il trattamento del rallentato metabolismo cerebrale

Publications (1)

Publication Number Publication Date
BE881680A true BE881680A (fr) 1980-05-30

Family

ID=26329263

Family Applications (1)

Application Number Title Priority Date Filing Date
BE0/199368A BE881680A (fr) 1979-02-12 1980-02-12 Composition pharmaceutique a base d'acylcarnitine pour le traitement d'un metabolisme cerebral altere et methode utilisee a cet effet

Country Status (8)

Country Link
US (1) US4346107A (enExample)
AU (1) AU535518B2 (enExample)
BE (1) BE881680A (enExample)
CH (1) CH641673A5 (enExample)
DE (1) DE3005208A1 (enExample)
FR (1) FR2448348A1 (enExample)
GB (1) GB2046593A (enExample)
NL (1) NL8000768A (enExample)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1198434B (it) * 1981-01-06 1988-12-21 Sigma Tau Ind Farmaceuti Composizione farmaceutica comprendente gamma butirrobetaina per il trattamento di sindromi da carenze di carnitina
IT1142934B (it) * 1981-11-06 1986-10-15 Sigma Tau Ind Farmaceuti Uso della carnitina e delle acilcarnitine inferiori nel trattamento terapeutico della patologia delle vene
IT1157238B (it) * 1982-10-29 1987-02-11 Sigma Tau Ind Farmaceuti Impiego di 1-carnitina per migliorare i paramenti biochimici e comportamentali dell'eta' senile
IT1150396B (it) * 1982-12-09 1986-12-10 Sigma Tau Ind Farmaceuti Impiego di alcanoil l-carnitine per il trattamento terapeutico di miopa tie e distrofie muscolari
CH655005A5 (it) * 1983-02-16 1986-03-27 Sigma Tau Ind Farmaceuti Composizione farmaceutica ad azione metabolica ed energetica utilizzabile in terapia cardiaca e vascolare.
IT1181682B (it) * 1985-06-11 1987-09-30 Sigma Tau Ind Farmaceuti Impiego di alcanoil l-carnitine per il trattamento terapeutico del parkinsonismo idiopatico o indotto
IT1184655B (it) * 1985-10-14 1987-10-28 Sigma Tau Ind Farmaceuti Imiego di acetil l-carnitina nel trattamento terapeutico degli stati di shock
IT1195852B (it) * 1986-07-04 1988-10-27 Sigma Tau Ind Farmaceuti Impiego di l-carnitina nel trattamento degli effetti tossici indotti dall'inalazione di alotano e di altri anestitici generali alogenati
IT1196564B (it) * 1986-08-04 1988-11-16 Sigma Tau Ind Farmaceuti Impiego di acetil l-carnitina nel trattamento terapeutico delle neuropatie periferiche
SE8701662L (sv) * 1987-04-22 1988-10-23 Gelder Nico M Van Saett och medel foer att behandla neurologiska sjukdomar, exempelvis migraen genom paaverkan av nervcellerna
IT1224842B (it) * 1988-12-27 1990-10-24 Sigma Tau Ind Farmaceuti Uso di derivati della l-carnitina nel trattamento terapeutico delle alterazioni degenerative del sistema nervoso
IT1230141B (it) * 1989-05-03 1991-10-14 Fidia Spa Impiego di derivati della fosfatidil carnitina per la preparazione di composizioni farmaceutiche aventi attivita' nella terapia delle patologie dell'uomo associate con un danno neuronale.
IT1244636B (it) * 1991-01-04 1994-08-08 Sigma Tau Ind Farmaceuti Uso dell'acetil l-carnitina nel trattamento terapeutico del coma e composizioni farmaceutiche utili in tale trattamento.
IT1263004B (it) * 1992-10-08 1996-07-23 Sigma Tau Ind Farmaceuti Impiego della l-carnitina e acil l-carnitine nel trattamento a lungo termine di pazienti diabetici non insulino-dipendenti.
JP4598203B2 (ja) * 1995-12-01 2010-12-15 ビーティージー・インターナショナル・リミテッド 脳機能改善剤
IT1284650B1 (it) * 1996-05-24 1998-05-21 Sigma Tau Ind Farmaceuti Farmaco a base di un derivato della carnitina per il trattamento della demenza di alzheimer in pazienti ad insorgenza precoce della patologia
US6323237B1 (en) 1997-03-17 2001-11-27 Btg International Limited Therapeutic compositions
US20090253781A1 (en) * 2002-05-24 2009-10-08 Btg International Limited Therapeutic compositions
DK1017379T3 (en) * 1997-03-17 2015-02-16 Btg Int Ltd Therapeutic compositions comprising ketone compounds and precursors thereof
US6316038B1 (en) 1997-03-17 2001-11-13 Btg International Limited Therapeutic compositions
IT1291127B1 (it) 1997-04-01 1998-12-29 Sigma Tau Ind Farmaceuti Integratore alimentare per soggetti dediti ad intensa e prolungata attivita' fisica
US5889055A (en) * 1997-04-04 1999-03-30 Howard; James R. L-carnitine and acetyl-L-carnitine combined for prevention and treatment of syndromes related to diseases of energy metabolism
US5869528A (en) * 1997-07-22 1999-02-09 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Therapeutical method for the treatment of attention-deficit/hyperactive disorders
IT1299195B1 (it) * 1998-06-25 2000-02-29 Sigma Tau Healthscience Spa Composizione ad attivita' neuroprotettiva per la prevenzione ed il trattamento delle alterazioni nervose e comportamentali legate a stati
IT1302365B1 (it) * 1998-10-09 2000-09-05 Sigma Tau Healthscience Spa Uso di carnitine e resveratrolo per produrre una composizione per laprevenzione o il trattamento terapeutico di alterazioni cerebrali
WO2001032168A1 (en) * 1999-11-03 2001-05-10 Juvenon, Inc. Method of treating benign forgetfulness
US20080009467A1 (en) * 2000-05-01 2008-01-10 Accera, Inc. Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimers disease and other diseases resulting from reduced neuronal metabolism
PT1292294E (pt) * 2000-05-01 2009-06-01 Accera Inc Utilização de triglicéridos de cadeia média para tratamento e prevenção da doença de alzheimer
US6835750B1 (en) 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
US20070179197A1 (en) * 2000-05-01 2007-08-02 Accera, Inc. Compositions and methods for improving or preserving brain function
SK15862003A3 (sk) * 2001-05-29 2004-06-08 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Použitie alkanoyl L-karnitínu na prípravu liečiva na liečenie anhedónie
US7407778B2 (en) * 2002-02-07 2008-08-05 Pettegrew Jay W Compounds, compositions and methods for treating neuropsychiatric disorders
US8894973B2 (en) * 2002-02-07 2014-11-25 Jay W. Pettegrew Method and system for differential diagnosis of chronic schizophrenia and chronic alcoholism
JP2005523269A (ja) * 2002-02-07 2005-08-04 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ 老人性うつ病の治療におけるカルニチン
US7700074B2 (en) * 2002-02-07 2010-04-20 Pettegrew Jay W Method and system for diagnosis of neuropsychiatric disorders including chronic alcoholism
US20100010336A1 (en) * 2002-02-07 2010-01-14 Pettegrew Jay W Method and system for diagnosis of neuropsychiatric disorders including attention deficit hyperactivity disorder (adhd), autism, and schizophrenia
US20050272812A1 (en) * 2002-02-07 2005-12-08 Pettegrew Jay W Methor for use of acetyl-L-carnitine (ALCAR) for treatment of depressive disorders in humans
WO2004110963A2 (en) * 2003-05-29 2004-12-23 Pettegrew Jay W Glycerophosphocholine and its derivatives for medical imaging neuropsychiatric disorders
US20060257842A1 (en) * 2003-05-29 2006-11-16 Pettegrew Jay W Cryopreservation media and molecules
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
GB0420856D0 (en) * 2004-09-20 2004-10-20 Ketocytonyx Inc Cns modulators
USD516320S1 (en) 2004-07-15 2006-03-07 The Procter & Gamble Company Surface pattern of a paper product
EP1778213B1 (en) 2004-07-16 2017-04-05 BTG International Limited A method for the synthesis of oligomeric compounds
WO2006020179A2 (en) * 2004-07-20 2006-02-23 Ketocytonyx Inc. Oligomeric ketone compounds
EP1778212A4 (en) * 2004-07-23 2010-12-08 Btg Int Ltd SACCHARIDES CETOGENES
WO2006098767A2 (en) * 2004-09-21 2006-09-21 Ketocytonyx Inc. Treatment of adhd
DK1796658T3 (en) * 2004-09-21 2016-06-27 Btg Int Ltd dopaminergic mimetics
USD510665S1 (en) 2004-09-29 2005-10-18 The Procter & Gamble Company Surface pattern for an embossed paper product
US20060252775A1 (en) * 2005-05-03 2006-11-09 Henderson Samuel T Methods for reducing levels of disease associated proteins
WO2007001883A2 (en) * 2005-06-20 2007-01-04 Accera, Inc. Method to reduce oxidative damage and improve mitochondrial efficiency
PT2500017T (pt) 2006-04-03 2017-11-14 Accera Inc Utilização de compostos cetogénicos para tratamento de comprometimento da memória associado à idade
CA3078084C (en) 2007-07-31 2023-08-15 Cerecin Inc. Use of genomic testing and ketogenic compounds for treatment of reduced cognitive function
WO2010003114A1 (en) * 2008-07-03 2010-01-07 Neuera Pharmaceuticals, Inc. Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders
PT2582368T (pt) * 2010-06-16 2018-06-04 Alfasigma Spa Acetil-carnitina, para utilização num método para o aumento da neurogénese em tecido neuronal
EP4149437A1 (en) 2020-05-15 2023-03-22 Alfasigma S.p.A. Composition comprising methylfolate
IT202100020729A1 (it) 2021-08-02 2023-02-02 Univ Degli Studi Di Napoli Federico Ii Preparazione combinata per il trattamento della malattia di Pompe

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE700864A (enExample) * 1967-07-03 1967-12-18
GB1256162A (en) * 1968-08-16 1971-12-08 Braun Fa B Improvements in and relating to liquid products for intravenous administration
US3810994A (en) * 1972-06-01 1974-05-14 Ethyl Corp Method and composition for treating obesity
JPS531812B2 (enExample) * 1972-12-07 1978-01-23
AU518617B2 (en) * 1977-04-29 1981-10-08 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Therapeutic application of acetyl-d, 1-carnitine
IT1143611B (it) * 1977-11-03 1986-10-22 Sigma Tau Ind Farmaceuti Applicazione della acetil-carnitina nella terapia delle affezioni cardiache di/tipo anossico,ischemico,cardiotossico e nelle sindromi aritmiche
FR2414914A1 (fr) * 1978-01-18 1979-08-17 Sigma Tau Ind Farmaceuti Utilisations therapeutiques nouvelles de l'acetyl-1-carnitine et d'autres derives acyles de la 1-carnitine
IT1156741B (it) * 1978-05-15 1987-02-04 Sigma Tau Ind Farmaceuti Applicazione terapeutica della carnitina e di alcuni derivati acilati della carnitina nell'emodialisi

Also Published As

Publication number Publication date
AU5526780A (en) 1980-08-21
US4346107A (en) 1982-08-24
FR2448348A1 (fr) 1980-09-05
NL8000768A (nl) 1980-08-14
DE3005208C2 (enExample) 1989-12-28
AU535518B2 (en) 1984-03-29
DE3005208A1 (de) 1980-08-21
CH641673A5 (it) 1984-03-15
GB2046593A (en) 1980-11-19

Similar Documents

Publication Publication Date Title
BE881681A (fr) Composition pharmaceutique a base d'acylcarnitine pour le traitement des maladies vasculaires peripheriques, et methode utilisee a cet effet
FR2311816A1 (fr) Procede et composition pour former des surfaces d'elastomere de silicone receptives a la peinture
MA18939A1 (fr) Procede de preparation d'un agent pour le traitement de theilerioses
FR2509613B1 (fr) Medicament a base d'insuline pour le traitement du diabete sucre
FR2577111B1 (fr) Machine pour le traitement des poireaux
FR2508034B1 (fr) Procede de preparation d'amides acryliques et methacryliques
FR2333515A1 (fr) Compositions pharmaceutiques pour le traitement des troubles du metabolisme du calcium
BE881208A (fr) Composition pharmaceutique pour le traitement de psoriasis et methode d'utilisation de celle-ci
FR2499408B1 (fr) Composition pharmaceutique pour le traitement de l'osteopathie, a base d'acide 6-amino-1-hydroxyhexane-1,1-diphosphonique
FR2575073B1 (fr) Appareil pour le traitement du pied d'athlete
IL95412A0 (en) Pharmaceutical compositions containing 5-methyl-isoxazole-4-carboxylic acid anilide derivatives and 2-hydroxy-ethylidene-cyano acetic acid anilide derivatives
FR2488135B1 (fr) Composition pharmaceutique a base de propylene-glycol et d'acetaminophene
FR2529081B1 (fr) Composition therapeutique a base d'acide 5-hydroxydecanoique ou d'un de ses derives pour le traitement des maladies cardiovasculaires
FR2558372B1 (fr) Composition medicamenteuse pour le traitement de l'acne
FR2614791B1 (fr) Association medicamenteuse a base de plantes et oligoelements pour le traitement de rhumatismes et etats inflammatoires
GB2105992B (en) Pharmaceutical composition for treatment of cardio-vascular diseases
BE856740A (fr) Nouvelle composition medicamenteuse pour le traitement de la lithiase biliaire
DE3362340D1 (en) A pharmaceutical composition and the use thereof for the treatment of inflammation
BE894228A (fr) Composition pharmaceutique pour le traitement de l'atherosclerose
EP0221428A3 (en) Liquid for the treatment of a photoresist composition, and process therefor
FR2517542B1 (fr) Medicament pour l'amelioration du metabolisme lipidique
BE851702A (fr) Procede et compositions pour le traitement d'etats pathologiques du cerveau
FR2562798B1 (fr) Agent pharmaceutique pour le traitement du psoriasis
GB2117238B (en) Morniflumate pharmaceutical compositions having antiinflammatory analgesic antipyretic and gastroprotective activity
BE892339A (fr) Agents pour le traitement d'affections cardiaques coronariennes

Legal Events

Date Code Title Description
RE20 Patent expired

Owner name: CAVAZZA CLAUDIO

Effective date: 20000212